MarketScreener Homepage > Equities > Euronext Growth Paris > Cellectis ALCLS FR0010425595

Report

Real-time Euronext Growth Paris - 01/18 11:35:02 am
26.25	EUR		+2.94%

01/14

01/13

01/11

Summary

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Within the weekly time frame the stock shows a bullish technical configuration above the support level at 13.68 EUR

Weaknesses

Stock prices approach a strong long-term resistance in weekly data at EUR 26.25.
Technically, the stock approaches a strong medium-term resistance at EUR 26.7.
Low profitability weakens the company.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Based on current prices, the company has particularly high valuation levels.

Ratings chart

Sector Biotechnology & Medical Research - NEC



MODERNA, INC.	24.10%	51 304
LONZA GROUP AG	3.27%	49 041
CELLTRION, INC.	-12.53%	40 715
IQVIA HOLDINGS INC.	4.81%	36 004
SEAGEN INC.	6.06%	33 601
HANGZHOU TIGERMED CONSULTIN..	0.43%	21 655
INCYTE CORPORATION	4.12%	19 832
ALNYLAM PHARMACEUTICALS, IN..	28.00%	19 328
PHARMARON BEIJING CO., LTD.	5.47%	15 119
CRISPR THERAPEUTICS AG	30.55%	14 233
CHARLES RIVER LABORATORIES ..	9.55%	13 616
BIO-TECHNE CORPORATION	9.50%	13 425
PPD, INC.	6.66%	12 762
QIAGEN N.V.	0.66%	12 098
ICON PUBLIC LIMITED COMPANY	7.88%	11 101

Financials

Upcoming event on CELLECTIS

03/15/21

Fundamental ratings

Technical ratings